000144449 001__ 144449
000144449 005__ 20240229112624.0
000144449 0247_ $$2doi$$a10.1016/j.ctro.2019.06.001
000144449 0247_ $$2pmid$$apmid:31341970
000144449 0247_ $$2pmc$$apmc:PMC6610684
000144449 037__ $$aDKFZ-2019-01901
000144449 041__ $$aeng
000144449 082__ $$a610
000144449 1001_ $$aTalbot, Christopher J$$b0
000144449 245__ $$aMulti-centre technical evaluation of the radiation-induced lymphocyte apoptosis assay as a predictive test for radiotherapy toxicity.
000144449 260__ $$aAmsterdam$$bElsevier$$c2019
000144449 3367_ $$2DRIVER$$aarticle
000144449 3367_ $$2DataCite$$aOutput Types/Journal article
000144449 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1565264509_14748
000144449 3367_ $$2BibTeX$$aARTICLE
000144449 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000144449 3367_ $$00$$2EndNote$$aJournal Article
000144449 520__ $$aPredicting which patients will develop adverse reactions to radiotherapy is important for personalised treatment. Prediction will require an algorithm or nomogram combining clinical and biological data. The radiation-induced lymphocyte apoptosis (RILA) assay is the leading candidate as a biological predictor of radiotherapy toxicity. In this study we tested the potential of the assay for standardisation and use in multiple testing laboratories. The assay was standardised and reproducibility determined using samples from healthy volunteers assayed concurrently in three laboratories in Leicester (UK), Mannheim (Germany) and Montpellier (France). RILA assays were performed on samples taken prior to radiotherapy from 1319 cancer patients enrolled in the REQUITE project at multiple centres. The patients were being treated for breast (n = 753), prostate (n = 506) or lung (n = 60) cancer. Inter-laboratory comparisons identified several factors affecting results: storage time, incubation periods and type of foetal calf serum. Following standardisation, there was no significant difference in results between the centres. Significant differences were seen in RILA scores between cancer types (prostate > breast > lung), by smoking status (non-smokers > smokers) and co-morbidity with rheumatoid arthritis (arthritics > non-arthritics). An analysis of acute radiotherapy toxicity showed as expected that RILA assay does not predict most end-points, but unexpectedly did predict acute breast pain. This result may elucidate the mechanism by which the RILA assay predicts late radiotherapy toxicity. The work shows clinical trials involving multiple laboratory measurement of the RILA assay are feasible and the need to account for tumour type and other variables when applying to predictive models.
000144449 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000144449 588__ $$aDataset connected to CrossRef, PubMed,
000144449 7001_ $$aVeldwijk, Marlon R$$b1
000144449 7001_ $$aAzria, David$$b2
000144449 7001_ $$aBatini, Chiara$$b3
000144449 7001_ $$aBierbaum, Miriam$$b4
000144449 7001_ $$aBrengues, Muriel$$b5
000144449 7001_ $$0P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aChang-Claude, Jenny$$b6$$udkfz
000144449 7001_ $$aJohnson, Kerstie$$b7
000144449 7001_ $$aKeller, Anke$$b8
000144449 7001_ $$aSmith, Sheila$$b9
000144449 7001_ $$aSperk, Elena$$b10
000144449 7001_ $$aSymonds, R Paul$$b11
000144449 7001_ $$aWenz, Frederik$$b12
000144449 7001_ $$aWest, Catharine M L$$b13
000144449 7001_ $$aHerskind, Carsten$$b14
000144449 7001_ $$aBourgier, Celine$$b15
000144449 773__ $$0PERI:(DE-600)2885426-3$$a10.1016/j.ctro.2019.06.001$$gVol. 18, p. 1 - 8$$p1 - 8$$tClinical and translational radiation oncology$$v18$$x2405-6308$$y2019
000144449 909CO $$ooai:inrepo02.dkfz.de:144449$$pVDB
000144449 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000144449 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000144449 9141_ $$y2019
000144449 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000144449 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000144449 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000144449 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review
000144449 915__ $$0LIC:(DE-HGF)CCBYNCNDNV$$2V:(DE-HGF)$$aCreative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND (No Version)$$bDOAJ
000144449 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lEpidemiologie von Krebserkrankungen$$x0
000144449 980__ $$ajournal
000144449 980__ $$aVDB
000144449 980__ $$aI:(DE-He78)C020-20160331
000144449 980__ $$aUNRESTRICTED